- Alpha Cognition Inc. (ACOG, Financial) announces promising preclinical results for ALPHA-1062 in treating mild traumatic brain injury (mTBI).
- Study indicates potential reduction in risk of Alzheimer's disease associated with mTBI.
- Research supported by US Department of Defense and conducted in collaboration with US Department of Veterans Affairs.
Alpha Cognition Inc. (Nasdaq: ACOG), a pioneering biopharmaceutical company, has unveiled positive preclinical data for its novel treatment, ALPHA-1062, aimed at addressing mild traumatic brain injury (mTBI). The study highlights the therapy's potential in reducing neuropathological indicators associated with mTBI, a prevalent condition among military personnel.
The data was gathered in collaboration with the US Department of Veterans Affairs and the Seattle Institute of Biomedical and Clinical Research, under the auspices of the US Department of Defense. Notably, the administration of ALPHA-1062 post-blast trauma markedly decreased three toxic forms of the brain protein Tau, critical markers that increase the risk of long-term cognitive decline and are early biomarkers in Alzheimer's disease.
In addition to this, the study revealed that ALPHA-1062 significantly reduces neuroinflammation by lowering myeloid cell counts and astrocytes, while it also increases the expression of nerve growth factor receptors in a dose-dependent manner. These findings align with previous research on moderate TBI models, reinforcing the therapeutic's protective effects and supporting its continued development.
Alpha Cognition is progressing towards completing the formulation of ALPHA-1062 for sublingual administration, with plans to conduct a bridging pharmacokinetic study against ZUNVEYL® (Benzgalantamine) and an existing intranasal formulation. The company remains committed to advancing treatments for neurodegenerative disorders, with a focus on mTBI and Alzheimer's disease.
